modelSilverCompounds
Extends from Pharmacolibrary.Drugs.ATC.S.S01AX02.
Information
| name: | SilverCompounds | |
| ATC code: | S01AX02 | route: |
| compartments: | 0 | |
| dosage: | 1 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | |
| other parameters in model implementation | ||
Silver compounds, such as silver nitrate and silver sulfadiazine, have been used as topical anti-infective agents, primarily for the treatment and prevention of infections in burn wounds and ulcerative lesions. Systemic use is not approved and is generally avoided due to toxicity concerns, including argyria (irreversible skin discoloration). Currently, silver compounds are used exclusively for topical application and are not approved for systemic pharmacotherapy.
Pharmacokinetics
References
Ellenikiotis, H, et al., & Milgrom, P (2022). Pharmacokinetics of 38 Percent Silver Diamine Fluoride in Children. Pediatric dentistry 44(2) 114–121. PUBMED:https://pubmed.ncbi.nlm.nih.gov/35484770
Chen, KF, et al., & Lin, YS (2020). Silver Diamine Fluoride in Children Using Physiologically Based PK Modeling. Journal of dental research 99(8) 907–913. DOI:10.1177/0022034520917368 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32374712
Ji, JH, et al., & Yu, IJ (2007). Twenty-eight-day inhalation toxicity study of silver nanoparticles in Sprague-Dawley rats. Inhalation toxicology 19(10) 857–871. DOI:10.1080/08958370701432108 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17687717
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)